Iovance Biotherapeutics Inc

Stock Chart, Company Information, and Scan Results

$5.42(as of Mar 9, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Iovance Biotherapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$5.42
Ticker SymbolIOVA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees975
CountyUSA
Market Cap$2,113.4M
EBIDTA-362.3M
10-Day Moving Average4.22
P/E Ratio-5.63
20-Day Moving Average3.45
Forward P/E Ratio0.00
50-Day Moving Average2.94
Earnings per Share-1.09
200-Day Moving Average2.42
Profit Margin-82.87%
RSI88.33
Shares Outstanding412.0M
ATR0.37
52-Week High5.63
Volume27,522,868
52-Week Low1.64
Most Recent Support Level3.57
Book Value698.6M
Most Recent Resistance Level3.91
P/B Ratio3.15
Upper Keltner4.29
P/S Ratio8.36
Lower Keltner2.61
Debt-to-Equity Ratio4.29
Next Earnings DateUnknown
Cash Surplus24.7M
Next Ex-Dividend DateUnknown

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Inc In Our Stock Scanner

As of Mar 09, 2026
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Discounted Stocks with Earnings GrowthScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.